BR112023023841A2 - Método para produzir derivado de di-hidropiridazina-3,5-diona - Google Patents

Método para produzir derivado de di-hidropiridazina-3,5-diona

Info

Publication number
BR112023023841A2
BR112023023841A2 BR112023023841A BR112023023841A BR112023023841A2 BR 112023023841 A2 BR112023023841 A2 BR 112023023841A2 BR 112023023841 A BR112023023841 A BR 112023023841A BR 112023023841 A BR112023023841 A BR 112023023841A BR 112023023841 A2 BR112023023841 A2 BR 112023023841A2
Authority
BR
Brazil
Prior art keywords
methyl
producing
dione derivative
hydropyranzine
diazaspiro
Prior art date
Application number
BR112023023841A
Other languages
English (en)
Portuguese (pt)
Inventor
Hiroshi Fukuda
Masatoshi Murakata
Satoshi Tanida
Shio Komiya
Taro Enomoto
Zengye Hou
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of BR112023023841A2 publication Critical patent/BR112023023841A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/001General concepts, e.g. reviews, relating to catalyst systems and methods of making them, the concept being defined by a common material or method/theory
    • B01J2531/002Materials
    • B01J2531/004Ligands
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/824Palladium
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/84Metals of the iron group
    • B01J2531/842Iron
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Epidemiology (AREA)
BR112023023841A 2021-06-08 2022-06-08 Método para produzir derivado de di-hidropiridazina-3,5-diona BR112023023841A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021096200 2021-06-08
PCT/JP2022/023068 WO2022260062A1 (ja) 2021-06-08 2022-06-08 ジヒドロピリダジン-3,5-ジオン誘導体の製造方法

Publications (1)

Publication Number Publication Date
BR112023023841A2 true BR112023023841A2 (pt) 2024-01-30

Family

ID=84426032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023841A BR112023023841A2 (pt) 2021-06-08 2022-06-08 Método para produzir derivado de di-hidropiridazina-3,5-diona

Country Status (13)

Country Link
US (1) US20250115585A1 (https=)
EP (1) EP4353718A4 (https=)
JP (1) JP7665747B2 (https=)
KR (1) KR20240019168A (https=)
CN (1) CN117460727A (https=)
AR (1) AR126060A1 (https=)
AU (1) AU2022291310A1 (https=)
BR (1) BR112023023841A2 (https=)
CA (1) CA3221272A1 (https=)
IL (1) IL309054A (https=)
MX (1) MX2023013898A (https=)
TW (1) TW202313590A (https=)
WO (1) WO2022260062A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525659B1 (en) * 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
CN102869656B (zh) 2010-04-28 2014-03-12 安斯泰来制药株式会社 四氢苯并噻吩化合物
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
KR101941048B1 (ko) 2011-10-27 2019-01-22 아스텔라스세이야쿠 가부시키가이샤 아미노 알킬 치환 n-티에닐벤즈아미드 유도체
WO2014003153A1 (ja) 2012-06-28 2014-01-03 協和発酵キリン株式会社 置換アミド化合物
PT2975030T (pt) * 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona
DE102013111551B3 (de) 2013-10-21 2015-01-22 Wago Verwaltungsgesellschaft Mbh Tragschienengehäuse
MX383069B (es) 2014-09-12 2025-03-13 Chugai Pharmaceutical Co Ltd Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
US10934280B2 (en) 2016-08-15 2021-03-02 Eli Lilly And Company Condensed thiophene derivatives useful as NaPi-IIb inhibitors
CN111801335A (zh) 2018-01-17 2020-10-20 株式会社神钢环境舒立净 亚硼酸酯化合物的合成方法、亚硼酸酯化合物的钠盐及其合成方法

Also Published As

Publication number Publication date
EP4353718A1 (en) 2024-04-17
JP7665747B2 (ja) 2025-04-21
EP4353718A4 (en) 2025-11-05
US20250115585A1 (en) 2025-04-10
IL309054A (en) 2024-02-01
CN117460727A (zh) 2024-01-26
MX2023013898A (es) 2023-12-11
WO2022260062A1 (ja) 2022-12-15
CA3221272A1 (en) 2022-12-15
AU2022291310A1 (en) 2024-01-18
JPWO2022260062A1 (https=) 2022-12-15
KR20240019168A (ko) 2024-02-14
TW202313590A (zh) 2023-04-01
AR126060A1 (es) 2023-09-06

Similar Documents

Publication Publication Date Title
MX2021014977A (es) Composicion de nicotina en bolsitas y bolsita que la comprende.
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
EA200901460A1 (ru) Способ получения порошка металлического титана
MY209048A (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CY1110977T1 (el) Υποκατεστημενα παραγωγα ινδολης για φαρμακευτικη συνθεση για θεραπεια ασθενειων του αναπνευστικου
BG102873A (en) Indole derivatives useful as endothelium receptor antagonists
DE502004009142D1 (de) Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen
ATE493427T1 (de) Neue mit fluor substituierte 1,4-benzothiepin-1,1-dioxidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CY1112826T1 (el) [4-(6-αλογονο-7-υποκατεστημενες-2,4-διοξο-1,4-διϋδρο-2η-κιναζολιν-3-υλ)-φαινυλ]-5-χλωρο-θειοφαιν-2-υλ-σουλφονυλουριες και μορφες και μεθοδοι που σχετιζονται με αυτες
CY1115373T1 (el) Παραγωγο αμινοϊνδανιου ή αλας αυτου
EA200600197A1 (ru) Получение производных соединения 1,3-дифенилпроп-2-ен-1-он
NO20021875D0 (no) Fremgangsmåte for stabilisering av benzimidazolforbindelser
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
SE0702522L (sv) Sammansättningar med förlängd frisättning och metoder för deras tillverkning
CY1108366T1 (el) Βενζοσουλφονικο αλας της 7-(2-(4-(3-τριφθορομεθυλ-φαινυλ-1,2,3,6-τετραϋδρο-πυριδ-1-υλ)αιθυλ)ισοκινολινης, η παρασκευη του και η χρηση του στη φαρμακευτικη αγωγη
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
CY1121986T1 (el) Στερεη φαρμακευτικη συνθεση κυtισινης και διαδικασια για την παρασκευη της
BR112023023841A2 (pt) Método para produzir derivado de di-hidropiridazina-3,5-diona
ATE518828T1 (de) Ein-topf-verfahren zur herstellung von 3-(2,2,2- trimethylhydrazinium)propionat-dihydrat
CY1108187T1 (el) Μεθοδος για την παρασκευη παραγωγων της (3-οξο 2,3-διυδρο-1η-ισοϊνδολ-1-υλο)-ακετυλογουανιδινης
WO2006052461A3 (en) Novel formulations of eprosartan with enhanced bioavailability
PL353681A1 (en) Applications of pyrrole derivatives in production of a drug
EP3845558A4 (en) ANTIBODY HALF-MOLECULE AND METHODS FOR INHIBITION OF HOMODIMER FORMATION OF ANTIBODY HALF-MOLECULE
IL287228A (en) A process for producing modified 2-[2-(phenyl)ethylamino]alkanamide derivatives

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.1 NA RPI NO 2841 DE 17/06/2025 POR TER SIDO INDEVIDA.